In vivo protection by broadly neutralizing HIV antibodies

Marit J van Gils; Rogier W Sanders

doi:10.1016/j.tim.2014.08.006

In vivo protection by broadly neutralizing HIV antibodies

Trends Microbiol. 2014 Oct;22(10):550-1. doi: 10.1016/j.tim.2014.08.006. Epub 2014 Aug 26.

Authors

Marit J van Gils¹, Rogier W Sanders²

Affiliations

¹ Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, The Netherlands.
² Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, The Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA. Electronic address: r.w.sanders@amc.uva.nl.

PMID: 25169020
DOI: 10.1016/j.tim.2014.08.006

Abstract

Passive immunization studies, including a recent one by Pegu et al., have repeatedly shown that HIV-specific broadly neutralizing antibodies (bnAbs) protect rhesus macaques from HIV acquisition. In vitro neutralization potency and in vivo protection correlate very strongly, supporting the quest for an HIV vaccine that induces potent bnAbs.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

AIDS Vaccines / immunology*
Animals
Antibodies, Neutralizing / immunology*
HIV Antibodies / immunology*
HIV Infections / prevention & control*
HIV-1 / immunology*
Humans
Immunization, Passive
Macaca mulatta

Substances

AIDS Vaccines
Antibodies, Neutralizing
HIV Antibodies